New radiation technique aims to ease brain cancer treatment side effects
NCT ID NCT05013892
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new type of whole brain radiation that spares healthy tissue, aiming to improve quality of life and reduce symptoms for people with brain metastases. About 41 adults with solid tumors and brain metastases will receive this radiation plus a standard drug. Researchers will track how patients feel using questionnaires.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 41 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2022
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Any patient with a solid tumor diagnosis and any number of brain metastasis clinically indicated for cranial irradiation with whole brain radiation therapy * Age ≥ 18 * Karnofsky Performance Status ≥ 70 * Prior stereotactic radiosurgery (SRS) permissible per physician discretion * Prior craniotomy permissible per physician discretion. Protocol radiation therapy should be initiated ≥2 weeks after craniotomy. * Prior partial brain radiation therapy permissible if target volume \< 50% brain and per physician discretion * Expectant \> 6 months survival * Ability to understand and the willingness to sign a written informed consent document. * Fluency in English, able to complete questionnaires and neurocognitive testing * Ability to undergo MRI with gadolinium examination * Ability to return for follow-up examinations throughout the course of this study for a maximum of 2 years after radiation treatment completion * Any prior, concomitant, or post-radiotherapy systemic therapy is permitted at discretion of treating physicians * Negative pregnancy test for premenopausal women Exclusion Criteria: * Leptomeningeal disease (by any one or more of clinical assessment, radiographic assessment, or cerebrospinal fluid study) * Prior whole brain radiation therapy * Pre-existing or current use of memantine or other NMDA antagonists * Known allergy to contrast used in imaging studies and/or inability to have MRI imaging * Uncontrolled intercurrent illness that could significantly affect baseline cognitive function as determined by the enrolling clinician, such as symptomatic congestive heart failure, unstable angina pectoris, prior CVA, significant uncontrolled epilepsy or psychiatric illness/social situations that would limit compliance with study requirements * Pregnant or unwilling to use appropriate contraception to prevent pregnancy during the time of radiation therapy * Concurrent participation in an investigational systemic therapy protocol.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Brain metastases are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Massachusetts General Hospital Cancer Center
RECRUITINGBoston, Massachusetts, 02114, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single day of brain radiation match five days?
- Can doctors watch brain metastases instead of zapping them?
- Starving brain tumors of blood before surgery
- Tiny gadolinium particles aim to make brain radiation hit harder
- A sharper MRI could reveal radiation sensitivity of brain tumors
- Expert tumor board may extend survival in brain metastases